To assess the relative BA of a low-strength FDC tablet formulation of niraparib plus AA compared to niraparib and AA co-administered as single agents after single dose administration and to assess BE of a regular strength FDC tablet formulation of niraparib plus AA compared to niraparib and AA co-administered as single agents at steady state in men with prostate cancer

2023-508150-26-00 Protocol 67652000PCR1001 Human pharmacology (Phase I) - Bioequivalence study Ongoing, recruitment ended

Start 26 Nov 2020 · Status Ongoing, recruitment ended · 3 EU/EEA countries · 4 sites · Protocol 67652000PCR1001

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Bioequivalence study
Status Ongoing, recruitment ended
Participants planned 141
Countries 3
Sites 4

Metastatic castration-resistant prostate cancer (mCRPC)

Key facts

Sponsor
Janssen Cilag International
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Male
Therapeutic area
Diseases [C] - Neoplasms [C04]
Trial duration
26 Nov 2020 → ongoing
Decision date (initial)
2024-05-06
Transition trial
Yes
Low-intervention
No
Rare-disease indication
No
Vulnerable population
No

External identifiers

EU CT number
2023-508150-26-00
EudraCT number
2019-000137-39

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Metastatic castration-resistant prostate cancer (mCRPC)

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Janssen Cilag International

Sponsor organisation
Janssen Cilag International
Address
Turnhoutseweg 30
City
Beerse
Postcode
2340
Country
Belgium

Scientific contact point

Organisation
Janssen Cilag International
Contact name
CTIS Point of Contact

Public contact point

Organisation
Janssen Cilag International
Contact name
CTIS Point of Contact

Locations

3 EU/EEA countries · 4 investigational sites

By country

CountryMS statusPlanned subjectsSites
Netherlands Ongoing, recruitment ended 11 1
Poland Ongoing, recruitment ended 19 2
Spain Ongoing, recruitment ended 11 1
Rest of world
Georgia, United States, Moldova, Republic of, Russian Federation, United Kingdom, Ukraine
100

Investigational sites

Netherlands

1 site · Ongoing, recruitment ended
Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)
medical oncology, Dr. Molewaterplein 40, 3015 GD, Rotterdam

Poland

2 sites · Ongoing, recruitment ended
Uniwersyteckie Centrum Kliniczne
Ośrodek Badań Klinicznych Wczesnych Faz, Ul. Mariana Smoluchowskiego 17, 80-214, Gdansk
Narodowy Instytut Onkologii Im. Marii Sklodowskiej-Curie Panstwowy Instytut Badawczy
Oddział Badań Wczesnych Faz, Ul. Wilhelma Konrada Roentgena 5, 02-781, Warsaw

Spain

1 site · Ongoing, recruitment ended
Hospital Universitario Virgen De La Victoria
MEDICAL ONCOLOGY DEPARTMENT. PHASE I CLINICAL TRIALS UNIT, Calle Del Arroyo Teatinos Sn, 29010, Malaga

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Netherlands 2020-12-07 2020-12-10 2021-10-01
Poland 2020-11-26 2021-01-11 2021-10-01
Spain 2021-02-08 2021-02-23 2021-10-01

Application history

3 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2024-03-28 Poland Acceptable
2024-05-06
2024-05-06
2 SUBSTANTIAL MODIFICATION SM-1 2024-09-12 Poland Acceptable
2024-10-28
2024-10-30
3 SUBSTANTIAL MODIFICATION SM-2 2025-09-25 Poland Acceptable
2025-11-07
2025-11-11